Enlivex Therapeutics Holds 2024 Annual Shareholder Meeting
Ticker: ENLV · Form: 6-K · Filed: Nov 8, 2024 · CIK: 1596812
Sentiment: neutral
Topics: shareholder-meeting, regulatory-filing, foreign-private-issuer
Related Tickers: ENRX
TL;DR
Enlivex held its 2024 shareholder meeting Nov 7th, filed as a foreign private issuer.
AI Summary
Enlivex Therapeutics Ltd. held its 2024 Annual General Meeting of Shareholders on November 7, 2024. The company, organized under the laws of Israel, is headquartered at 14 Einstein Street, Nes Ziona, Israel. This filing is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Why It Matters
This filing confirms the company's adherence to regulatory reporting requirements for foreign private issuers and provides an update on corporate governance through its annual shareholder meeting.
Risk Assessment
Risk Level: low — This is a routine filing reporting on a shareholder meeting, not indicating new financial or operational risks.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- November 7, 2024 (date) — Date of Annual General Meeting
- Israel (location) — Country of Incorporation and Headquarters
- 14 Einstein Street, Nes Ziona, Israel 7403618 (address) — Principal executive offices
- 001-36578 (other) — Commission file number
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of November 2024.
When did Enlivex Therapeutics Ltd. hold its 2024 Annual General Meeting of Shareholders?
The 2024 Annual General Meeting of Shareholders was held on November 7, 2024.
Under which jurisdiction is Enlivex Therapeutics Ltd. organized?
Enlivex Therapeutics Ltd. is organized under the laws of the State of Israel.
What is the company's principal executive office address?
The principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel 7403618.
Does Enlivex Therapeutics Ltd. file annual reports under Form 20-F or 40-F?
The company indicates it files annual reports under cover of Form 20-F.
Filing Stats: 297 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2024-11-08 16:30:09
Filing Documents
- ea0220412-6k_enlivex.htm (6-K) — 10KB
- 0001213900-24-095924.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer Date: November 8, 2024 2